LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time

By LabMedica International staff writers
Posted on 03 Aug 2020
Print article
Image: New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time (Photo courtesy of FSVO/Renate Boss)
Image: New Rapid Test Determines Amount of Neutralizing Antibodies Against SARS-CoV-2 Within Short Period of Time (Photo courtesy of FSVO/Renate Boss)
A Swiss-German team of researchers have developed a test that determines the amount of neutralizing antibodies against SARS-CoV-2 within a short period of time.

The test was developed at the Institute of Virology and Immunology (IVI) of the University of Bern (Bern, Switzerland) and the Swiss Federal Office for Food Safety and Animal Health (Köniz, Switzerland), and evaluated by the Ruhr-University Bochum (RUB Bochum, Germany) using serum samples from COVID-19 patients.

To determine immunity to SARS-CoV-2 and the effectiveness of potential vaccines, the amount of neutralizing antibodies in the blood of recovered or vaccinated individuals must be determined. A traditional neutralization test usually takes two to three days and must be carried out with infectious coronaviruses in a laboratory complying with biosafety level 3. The new test launched by the team of Swiss-German researchers takes only 18 hours and does not have high biosafety requirements.

In order to detect antibodies against SARS-CoV-2, the researchers used another virus that does not propagate and exchanged the envelope protein of this virus for the spike protein of the novel coronavirus, which mediates virus entry and infection. As a result, the viruses can be identified by antibodies against SARS-CoV-2 that bind to the viruses which have been altered in this way and neutralize them so that they can no longer penetrate the host cells. Since the virus pseudotyped in this way cannot propagate in host cells, no elaborate biosafety precautions are necessary for the test.

In order to determine the amount of antibodies, the researchers genetically modified the virus so that green fluorescent protein and luciferase, an enzyme from fireflies, will be produced by the infected cells. The green fluorescence is an indicator of infection with the pseudotyped virus. The less green cells found, the more neutralizing antibodies are present which block the virus. In addition, a luminometer can be used to read the luminescence signal produced by the luciferase enzyme – another way of evaluating the test.

In order to check the reliability and comparability with the conventional neutralization test, the researchers applied it to blood samples from COVID-19 patients. The direct comparison showed a good correlation between the two test systems. As compared to 56 hours for the conventional test, the new test is much faster, with only 18 hours to test results.

Related Links:
University of Bern
Swiss Federal Office for Food Safety and Animal Health
Ruhr-University Bochum


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more